Valuation: Acadia Pharmaceuticals Inc.

Market Cap 3.24B 2.94B 2.72B 2.45B 4.62B 306B 4.78B 32.63B 12.94B 163B 12.16B 11.9B 518B P/E 2026 *
24.4x
P/E 2027 * 18.8x
Enterprise Value 2.24B 2.03B 1.88B 1.69B 3.19B 211B 3.31B 22.56B 8.94B 113B 8.41B 8.23B 358B EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.38x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day+3.36%
1 week-11.68%
Current month-8.94%
1 month+0.70%
3 months-33.93%
6 months-15.46%
Current year-29.80%
1 week 15.86
Extreme 15.855
21.66
1 month 15.86
Extreme 15.855
22.63
Current year 15.86
Extreme 15.855
30.96
1 year 15.86
Extreme 15.855
30.96
3 years 13.4
Extreme 13.4
32.59
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 20/09/2024
Director of Finance/CFO 52 10/09/2021
Chief Tech/Sci/R&D Officer - 04/08/2025
Director TitleAgeSince
Director/Board Member 68 01/05/2008
Chairman 55 10/06/2016
Director/Board Member 73 25/11/2015
Date Insider Type Main position Quantity % Market Cap. Importance
30/10/26 Sell

Chief Financial Officer

-3,321 0.0019%
6/8/26 Exercice

Chief Financial Officer

42,876 0.0250%
30/7/26 Sell

Chief Technology Officer

-16,558 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
+3.36%-11.68%-20.69%-16.37% 3.24B
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average -0.22%-1.12%+31.92%+168.14% 41B
Weighted average by Cap. -0.79%+0.11%+36.77%+160.78%

Financials

2026 *2027 *
Net sales 1.28B 1.16B 1.07B 968M 1.83B 121B 1.89B 12.89B 5.11B 64.5B 4.81B 4.7B 205B 1.45B 1.32B 1.22B 1.1B 2.07B 137B 2.14B 14.62B 5.8B 73.12B 5.45B 5.33B 232B
Net income 134M 121M 112M 101M 191M 12.63B 198M 1.35B 535M 6.75B 503M 492M 21.42B 174M 158M 146M 132M 249M 16.45B 257M 1.76B 696M 8.78B 655M 641M 27.89B
Net Debt -1B -906M -838M -756M -1.43B -94.31B -1.48B -10.07B -3.99B -50.38B -3.75B -3.67B -160B -1.23B -1.12B -1.03B -933M -1.76B -116B -1.82B -12.42B -4.93B -62.15B -4.63B -4.53B -197B
Projected Income Statement - Annual - Acadia Pharmaceuticals Inc.
Logo Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
13/11/26 US$18.75 +3.36% 1,785,340
12/11/26 US$18.14 -1.25% 1,934,198
11/11/26 US$18.37 +0.49% 2,395,219
10/11/26 US$18.28 +10.79% 6,354,161
09/11/26 US$16.50 -22.28% 12,150,928
Trader
Investor
Global
Quality
ESG MSCI
B
MarketScreener Ratings - Acadia Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
18.75USD
Average target price
30.32USD
Spread / Average Target
+61.68%
  1. Stock Market
  2. Stocks
  3. ACAD Stock